South Asian Journal of Cancer

DRUG REVIEW
Year
: 2014  |  Volume : 3  |  Issue : 3  |  Page : 182--184

Tolvaptan


Bharath Rangarajan1, Vineetha Binoy1, Sachin Sharatchandra Hingmire2, Vanita Noronha3 
1 Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka, India
2 Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, India
3 Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

Correspondence Address:
Bharath Rangarajan
Department of Medical Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka
India

Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan. Vaptans including Tolvaptan act as «DQ»aquaretic«DQ» agents cousing excretion of water while retaining the sodium. Administration of this agent for prescribed periods result in improvement of serum sodium levels. The drug can be used in many clinical situations resulting in hyponatremia including congestive heart failure, cirrhosis and syndrome of inappropriate ADH secretion (SIADH) including SIADH related to malignancies.


How to cite this article:
Rangarajan B, Binoy V, Hingmire SS, Noronha V. Tolvaptan.South Asian J Cancer 2014;3:182-184


How to cite this URL:
Rangarajan B, Binoy V, Hingmire SS, Noronha V. Tolvaptan. South Asian J Cancer [serial online] 2014 [cited 2020 Feb 17 ];3:182-184
Available from: http://journal.sajc.org/article.asp?issn=2278-330X;year=2014;volume=3;issue=3;spage=182;epage=184;aulast=Rangarajan;type=0